公开(公告)号：US20200262814A1

公开(公告)日：2020-08-20

申请号：US16666108

申请日：2019-10-28

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: C07D401/14 ,  A61K45/06 ,  A61P35/00 ,  A61K31/506 ,  A61P31/04 ,  C07D413/14 ,  A61K31/497

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US10508101B2

公开(公告)日：2019-12-17

申请号：US16354416

申请日：2019-03-15

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: A61K31/497 ,  C07D401/14 ,  C07D413/14 ,  A61P31/04 ,  A61K31/506 ,  A61P35/00 ,  A61K45/06

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US20210387962A1

公开(公告)日：2021-12-16

申请号：US17200509

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: C07D401/14 ,  A61K31/497 ,  C07D413/14 ,  A61P31/04 ,  A61K31/506 ,  A61P35/00 ,  A61K45/06

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US20190202809A1

公开(公告)日：2019-07-04

申请号：US16354416

申请日：2019-03-15

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: C07D401/14 ,  C07D413/14 ,  A61P35/00 ,  A61K31/497 ,  A61P31/04 ,  A61K31/506

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US09845309B2

公开(公告)日：2017-12-19

申请号：US15237880

申请日：2016-08-16

Applicant: NOVARTIS AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: C07D401/14 ,  A61K31/497 ,  C07D413/14

CPC classification number: C07D401/14 ,  A61K31/497 ,  C07D413/14

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US11505541B2

公开(公告)日：2022-11-22

申请号：US17200509

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: A61K31/497 ,  C07D401/14 ,  C07D413/14 ,  A61P31/04 ,  A61K31/506 ,  A61P35/00 ,  A61K45/06

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US20240308979A1

公开(公告)日：2024-09-19

申请号：US18483436

申请日：2023-10-09

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: C07D401/14 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  A61P31/04 ,  A61P35/00 ,  C07D413/14

CPC classification number: C07D401/14 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  A61P31/04 ,  A61P35/00 ,  C07D413/14

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

公开(公告)号：US11059804B2

公开(公告)日：2021-07-13

申请号：US16666108

申请日：2019-10-28

Applicant: Novartis AG

Inventor： Michael Joseph Luzzio ,  Julien Papillon ,  Michael Scott Visser

IPC: A61K31/497 ,  C07D401/14 ,  C07D413/14 ,  A61P31/04 ,  A61K31/506 ,  A61P35/00 ,  A61K45/06

Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.